|
AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said their drug Datroway significantly improved survival outcomes for patients with a hard-to-treat form of breast cancer, marking a potential advance in treatment options. AstraZeneca, a Cambridge, England-based pharmaceutical company said results from the phase III Tropion-Breast02 trial showed Datroway, datopotamab deruxtecan, delivered a statistically significant and clinically meaningful improvement in both overall survival and progression-free survival compared with chemotherapy in patients with metastatic triple-negative breast cancer who were not eligible for immunotherapy. AstraZeneca said Datroway is the first and only therapy to show an overall survival benefit over chemotherapy in this patient population. Around 70% of metastatic triple-negative breast cancer patients are not candidates for immunotherapy, the company added. Susan Galbraith, executive vice president of oncology R&D at AstraZeneca, said: ‘Tropion-Breast02 is the only trial ever to show an overall survival benefit in the first-line treatment of patients with metastatic triple-negative breast cancer for whom immunotherapy is not an option. We expect today’s results will mark an inflection point in the treatment of these patients who have the poorest prognosis of any type of breast cancer and urgently need better options.’ Daiichi Sankyo’s Global Head of R&D Ken Takeshita said Datroway was ‘the first antibody-drug conjugate and the only therapy’ to significantly improve overall survival versus chemotherapy in these patients. He said the partners will discuss the results with regulators to bring the treatment to patients ‘as soon as possible.’ The safety profile of Datroway was consistent with prior studies, AstraZeneca noted. The results will be presented at an upcoming medical meeting and submitted to regulatory authorities. Datroway is a Trop2-directed antibody-drug conjugate jointly developed and commercialised by AstraZeneca and Tokyo-based pharmaceutical firm Daiichi Sankyo. The partners are studying the drug in additional phase III trials across various stages of triple-negative breast cancer and other tumour types. Shares in AstraZeneca opened 0.8% higher at 12,756.10 pence in London on Monday. In Tokyo, Daiichi Sankyo shares closed up 4.8% at JP¥3,905.00, supported by the broader Nikkei 225 index, which also rose 4.8% after Sanae Takaichi was elected leader of the ruling Liberal Democratic Party. She is expected to be confirmed by parliament as prime minister of Japan around October 15. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
